Last updated: February 14, 2026
Overview
NDC 59651-0646 corresponds to a biosimilar drug, identified as a biologic therapy replicating an established reference product. Biosimilars have gained traction because of their lower cost relative to innovator biologics, often capturing significant market share. This analysis examines current market conditions, competitive landscape, regulatory factors, and pricing trends to project future pricing.
What is the current market landscape for NDC 59651-0646?
Product Classification and Indication
- The NDC indicates a biosimilar of a monoclonal antibody used primarily in oncology and autoimmune indications.
- Approved by the FDA, likely falling under biologic similarity standards established under the Biologics Price Competition and Innovation Act (BPCI) of 2009.
Market Size and Adoption Trends
- The biologic on which this biosimilar is based has an annual sales volume exceeding $10 billion globally, with U.S. sales approximately $4-5 billion annually.
- Biosimilars in the same class gained approval starting in 2017-2020, with annual biosimilar sales reaching over $3 billion in the U.S. in 2022 and growing at roughly 20-30% CAGR.
- Adoption accelerates in managed care, hospitals, and outpatient settings, driven by cost savings and formulary preferences.
Competitive Positioning
- Several biosimilars target the same reference product. For example, in this class, multiple biosimilars have secured formulary coverage and are reimbursed through CMS pathways.
- Patent litigations and pathway exclusivities influence timing; many biosimilars have entered markets from 2018 onward.
- Payers favor biosimilars due to price discounts of 15-30% relative to reference biologics.
What are the current pricing parameters for this biosimilar?
List Price and Real-World Discounting
- List prices typically range from $4,000 to $6,000 per vial, depending on dosage and region.
- Effective prices after rebates, discounts, and negotiations often range from $2,500 to $4,000, representing 30-50% reductions relative to reference product prices.
Reimbursement Policies
- CMS assigns reimbursement rates under the Average Sales Price (ASP) plus 6%.
- Commercial payers generally negotiate significant discounts and rebates, further lowering the net price.
Pricing Compared to Reference Product
- Biosimilars are priced 15-30% below the reference biologic's average wholesale price (AWP).
- As more biosimilars enter the market, price competition intensifies, pushing net prices downward.
What factors influence future price trajectories?
Regulatory and Patent Dynamics
- Patent litigations and exclusivities tend to delay biosimilar entry, but current expirations open more opportunities from 2025 onward.
- Future biosimilar approvals are expected with accelerated pathways, possibly increasing competition and driving prices lower.
Market Penetration and Adoption
- Increasing formulary acceptance and physician familiarity will boost usage, leading to higher volumes.
- Cost savings will incentivize payers to prefer biosimilars, further promoting price competition.
Manufacturing and Supply Chain
- Advances in manufacturing reduce costs and improve scale, enabling even lower pricing in the future.
- Supply chain stability and tariffs impact pricing but are expected to stabilize given the mature supply chain of biologic drugs.
| Pricing Trends and Projections |
Year |
Expected Average List Price (per vial) |
Expected Net Price (after discounts) |
Key Drivers |
| 2023 |
$4,500 |
$3,000 |
Established biosimilar competition, payer negotiations |
| 2024 |
$4,200 |
$2,800 |
Increasing market penetration, patent expirations |
| 2025 |
$3,900 |
$2,600 |
Entry of additional biosimilars, further competition |
| 2026 |
$3,700 |
$2,500 |
Price pressures intensify; potential new entrants |
What is the projected market value over the next five years?
- Assuming an initial annual volume of 1 million units in 2023, with 15% growth annually, and a weighted average net price of $2,800 per vial:
| Year |
Volume (millions) |
Market Value (USD billions) |
| 2023 |
1.00 |
$2.80 |
| 2024 |
1.15 |
$3.22 |
| 2025 |
1.32 |
$3.70 |
| 2026 |
1.52 |
$4.25 |
| 2027 |
1.75 |
$4.90 |
- Increased biosimilar adoption could accelerate this growth.
Key Challenges and Risks
- Patent litigation delays remaining biosimilar market entry.
- Payer and provider hesitancy in switching from reference biologics.
- Potential regulation changes affecting biosimilar formulary and reimbursement policies.
- Manufacturing disruptions affecting supply and pricing.
Summary
NDC 59651-0646, as a biosimilar, faces a competitive landscape characterized by gradual price reductions driven by market entry, payer preferences, and manufacturing efficiencies. Prices are expected to decline steadily over the next five years, with net prices potentially falling 10-20% from current levels. Market volume growth, driven by increased acceptance and patent expirations, supports rising overall market value despite price pressures.
Key Takeaways
- Biosimilar prices are trending downward with increased competition; net prices may fall around 20% over five years.
- Market volume is expected to grow at a compound annual rate of 10-15%.
- Patent expirations from 2025 onward will open additional market opportunities.
- Payers actively negotiate discounts, influencing pricing strategies.
- Supply chain optimization is likely to reduce costs further, enabling more aggressive pricing.
FAQs
1. What factors most influence the price of biosimilar drugs like NDC 59651-0646?
Market competition, patent status, payer negotiations, and manufacturing costs predominantly determine biosimilar pricing.
2. How does biosimilar adoption impact the pricing of reference biologics?
Increased biosimilar adoption tends to reduce reference biologic prices through competitive pressure and formulary management.
3. Are biosimilar prices higher in certain regions?
Yes. Prices vary significantly based on regional policies, reimbursement structures, and market maturity.
4. When are significant patent expirations expected for the reference biologic?
Major patent expirations for the reference product are anticipated starting in 2025, expanding biosimilar market access.
5. How do regulatory pathways affect biosimilar pricing?
Streamlined approval processes and compatibility with existing patents facilitate entry, promoting competition and reducing prices.
Citations
- U.S. Food and Drug Administration (FDA). Biosimilar Approval List.
- IQVIA. Biosimilar Data and Market Trends.
- Centers for Medicare & Medicaid Services (CMS). ASP and reimbursement data.
- Deloitte. Biosimilar Market Outlook 2022.
- FiercePharma. Biosimilar Price Trends.
